The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
Ovarian Cancer Immunotherapy and Personalized Medicine
Open accessAbstract
Ovarian cancer response to immunotherapy is limited; however, the evaluation of sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may improve the predictiveness of response to immunotherapy. These markers include tumor mutation burden, PD-L1, tumor-infiltrating lymphocytes, homologous recombination deficiency, and neoantigen intratumoral heterogeneity. Future directions in the treatment of ovarian cancer include the utilization of these biomarkers to select ideal candidates. This paper reviews the role of immunotherapy in ovarian cancer as well as novel therapeutics and study designs involving tumor biomarkers that increase the likelihood of success with immunotherapy in ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Cancer cells upregulate immune checkpoints, thereby decreasing the local immune response and permitting immune evasion [9,10].”
BackgroundType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552 · cited 1×
“Recently, pembrolizumab, a monoclonal antibody targeting PD-1, was approved for use in any TMB-high (≥10) tumor, regardless of histology [27,28].”
BackgroundTumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · cited 1×
“found that high clonal neoantigen burden combined with low neoantigen intratumoral heterogeneity portended a good prognosis in patients with NSCLC and melanoma receiving anti-PD-1 or anti-CTLA-4 antibodies [33,69].”
BackgroundSato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,263
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Tertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,707
Epithelial-Mesenchymal Transitions
Kang, Y., & Massagué, J. (2004) · Cell · doi:10.1016/j.cell.2004.07.011 · Cited by 1,525
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
The Human Genome Project: Lessons from Large-Scale Biology
Collins, F. S., Morgan, M., & Patrinos, A. (2003) · Science · doi:10.1126/science.1084564 · Cited by 1,284 · cited 1×
“OLAPem [137] Phase II, single-arm, open-label trial studying the use of olaparib monotherapy and olaparib and pembrolizumab combination therapy in ovarian cancer Arm 1, Cohort 1: Olaparib before surgery”
MethodGong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,273
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Woo, E. Y., Chu, C., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., & June, C. H. (2001) · PubMed · Cited by 1,108
Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095
Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues.
Weitman, S. D., Lark, R. H., Coney, L. R., Fort, D. W., Frasca, V., Zurawski, V. R., & Kamen, B. A. (1992) · PubMed · Cited by 1,011
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
Pagès, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., Lagorce, C., Wind, P., Marliot, F., Bruneval, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6147 · Cited by 954
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Diaz, L. A., Shiu, K.-K., Kim, T.-W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00197-8 · Cited by 945
Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 943
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
Tumor-infiltrating lymphocytes in the immunotherapy era
Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 880
Matulonis, U. A., Shapira-Frommer, R., Santin, A. D., Lisyanskaya, A. S., Pignata, S., Vergote, I., Raspagliesi, F., Sonke, G. S., Birrer, M., Provencher, D. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz135 · Cited by 845
Nywening, T. M., Wang-Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Cusworth, B. M., Toriola, A. T., Nieman, R. K., Worley, L. A., Yano, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00078-4 · Cited by 807
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S., & Coukos, G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.039 · Cited by 661
Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M., Karin, M., Goldrath, A. W., & Johnson, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1439 · Cited by 652
Dunphy, G., Flannery, S. M., Almine, J. F., Connolly, D. J., Paulus, C., Jønsson, K. L., Jakobsen, M. R., Nevels, M. M., Bowie, A. G., & Unterholzner, L. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.034 · Cited by 648 · cited 1×
“This ATM-TRAF6 also mediates the further upregulation of PD-L1, which partly explains the dearth of immune activation in ovarian cancer [15,64].”
BackgroundDNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645
Advances in ovarian cancer therapy
Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3501-8 · Cited by 624
Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
Differences in Breast Cancer Survival by Molecular Subtypes in the United States
Howlader, N., Cronin, K. A., Kurian, A. W., & Andridge, R. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0627 · Cited by 598
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Yarchoan, M., Albacker, L. A., Hopkins, A. C., Montesion, M., Murugesan, K., Vithayathil, T. T., Zaidi, N., Azad, N. S., Laheru, D. A., Frampton, G. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126908 · Cited by 545
Overexpression of folate binding protein in ovarian cancers
Toffoli, G., Cernigoi, C., Russo, A., Gallo, A., Bagnoli, M., & Boiocchi, M. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970422)74:2<193::aid-ijc10>3.0.co;2-f · Cited by 521
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi, J. L., Bobisse, S., Ophir, E., Tuyaerts, S., Roberti, A., Genolet, R., Baumgartner, P., Stevenson, B. J., Iseli, C., Dangaj, D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao5931 · Cited by 450
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
Salmaninejad, A., Valilou, S. F., Shabgah, A. G., Aslani, S., Alimardani, M., Pasdar, A., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28358 · Cited by 445
STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
Kusmartsev, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4880 · Cited by 445
Disis, M. L., Taylor, M. H., Kelly, K., Beck, J. T., Gordon, M., Moore, K. M., Patel, M. R., Chaves, J., Park, H., Mita, A. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6258 · Cited by 437
The folate receptor as a rational therapeutic target for personalized cancer treatment
Assaraf, Y. G., Leamon, C. P., & Reddy, J. A. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.10.002 · Cited by 398
Tumor infiltrating lymphocytes in ovarian cancer
Santoiemma, P. P., & Powell, D. J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1040960 · Cited by 337
Ten-Year Relative Survival for Epithelial Ovarian Cancer
Baldwin, L. A., Huang, B., Miller, R. W., Tucker, T., Goodrich, S. T., Podzielinski, I., DeSimone, C. P., Ueland, F. R., van Nagell, J. R., & Seamon, L. G. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318264f794 · Cited by 336
Biomarkers for Homologous Recombination Deficiency in Cancer
Hoppe, M. M., Sundar, R., Tan, D. S. P., & Jeyasekharan, A. D. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy085 · Cited by 329
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Granier, C., De Guillebon, E., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S., & Tartour, E. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000213 · Cited by 324
Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
Maibach, F., Sadozai, H., Seyed Jafari, S. M., Hunger, R. E., & Schenk, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02105 · Cited by 312
Human tumor antigens for cancer vaccine development
Wang, R., & Rosenberg, S. A. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01331.x · Cited by 296
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
Moschetta, M., George, A., Kaye, S. B., & Banerjee, S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw142 · Cited by 292
CD40 stimulation obviates innate sensors and drives T cell immunity in cancer
Byrne, K. T., & Vonderheide, R. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.058 · Cited by 282 · cited 15×
“Thus, high neoantigen burden combined with homogeneity, or low neoantigen ITH, is associated with an inflamed TME as well as modulation of the immune system, indicating an association between immunoediting and ITH score.”
BackgroundInfluentialClarke, B., Tinker, A. V., Lee, C.-H., Subramanian, S., van de Rijn, M., Turbin, D., Kalloger, S., Han, G., Ceballos, K., Cadungog, M. G., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2008.191 · Cited by 280
Drilon, A., Wang, L., Arcila, M. E., Balasubramanian, S., Greenbowe, J. R., Ross, J. S., Stephens, P., Lipson, D., Miller, V. A., Kris, M. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2683 · Cited by 274
Colbeck, E. J., Ager, A., Gallimore, A., & Jones, G. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01830 · Cited by 252
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250 · cited 1×
“Previously, autologous TILs therapy has been shown to be effective in melanoma [82,83].”
BackgroundDeveloping neoantigen-targeted T cell–based treatments for solid tumors
Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 238
Methods of measurement for tumor mutational burden in tumor tissue
Meléndez, B., Van Campenhout, C., Rorive, S., Remmelink, M., Salmon, I., & D’Haene, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.02 · Cited by 233
Moore, K. N., Martin, L. P., O’Malley, D. M., Matulonis, U. A., Konner, J. A., Perez, R. P., Bauer, T. M., Ruiz-Soto, R., & Birrer, M. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9538 · Cited by 226
Loss of E-Cadherin-Dependent Cell–Cell Adhesion and the Development and Progression of Cancer
Bruner, H. C., & Derksen, P. W. B. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a029330 · Cited by 213
Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer
Senzer, N., Barve, M., Kuhn, J., Melnyk, A., Beitsch, P., Lazar, M., Lifshitz, S., Magee, M., Oh, J., Mill, S. W., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.269 · Cited by 198
Self-citationRisk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples
Riester, M., Wei, W., Waldron, L., Culhane, A. C., Trippa, L., Oliva, E., Kim, S.-H., Michor, F., Huttenhower, C., Parmigiani, G., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju048 · Cited by 195
Andre, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.18_suppl.lba4 · Cited by 194
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Keung, M., Wu, Y., & Vadgama, J. V. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040435 · Cited by 169
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Choucair, K., Morand, S., Stanbery, L., Edelman, G., Dworkin, L., & Nemunaitis, J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 164
Self-citationVergote, I., Armstrong, D., Scambia, G., Teneriello, M., Sehouli, J., Schweizer, C., Weil, S. C., Bamias, A., Fujiwara, K., Ochiai, K., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2596 · Cited by 163
Ovarian Cancer Immunotherapy: Turning up the Heat
Ghisoni, E., Imbimbo, M., Zimmermann, S., & Valabrega, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122927 · Cited by 161
Immunotherapy for Ovarian Cancer: What's Next?
Kandalaft, L. E., Powell, D. J., Singh, N., & Coukos, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2369 · Cited by 154
Management strategies for recurrent platinum-resistant ovarian cancer
Naumann, R. W., & Coleman, R. L. (2011) · Drugs · doi:10.2165/11591720-000000000-00000 · Cited by 152
Frey, M. K., & Pothuri, B. (2017) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-017-0039-8 · Cited by 151
Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
Bonadio, R. R. D. C. C., Fogace, R. N., Miranda, V. D. C., & Estevez-Diz, M. D. P. (2018) · Clinics · doi:10.6061/clinics/2018/e450s · Cited by 148
Sabbatini, P. J., Harter, P., Scambia, G., Sehouli, J., Meier, W., Wimberger, P., Baumann, K., Kurzeder, C., Schmalfeldt, B., Cibula, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4057 · Cited by 145
Forget, M., Haymaker, C., Hess, K. R., Meng, Y. J., Creasy, C. A., Karpinets, T. V., Fulbright, O. J., Roszik, J., Woodman, S. E., Kim, Y. U., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3649 · Cited by 143
van Houdt, I. S., Sluijter, B. J. R., Moesbergen, L. M., Vos, W., de Gruijl, T. D., Molenkamp, B. G., van den Eertwegh, A. J. M., Hooijberg, E., van Leeuwen, P. A. M., Meijer, C. J. L. M., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23543 · Cited by 138
Recurrent epithelial ovarian cancer: an update on treatment.
Foley, O., Rauh‐Hain, J. A., & Carmen, M. G. D. (2013) · PubMed · Cited by 135
Zhao, X., Fang, Y., Yang, Y., Yu, Q., Wu, P., Wang, T., Lai, H., Li, M., Wang, D. W., Zheng, Z., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1017185 · Cited by 131
Hillen, F., Baeten, C. I. M., van de Winkel, A., Creytens, D., van der Schaft, D. W. J., Winnepenninckx, V. J. L., & Griffioen, A. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0353-9 · Cited by 126
Rocconi, R. P., Grosen, E. A., Ghamande, S. A., Chan, J. K., Barve, M. A., Oh, J., Tewari, D. S., Morris, P. C., Stevens, E., Bottsford-Miller, J. N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30533-7 · Cited by 124
Self-citationIntraepithelial T cells and tumor proliferation
Adams, S. F., Levine, D. A., Cadungog, M. G., Hammond, R., Facciabene, A., Olvera, N., Rubin, S. C., Boyd, J. A., Gimotty, P. A., & Coukos, G. (2009) · Cancer · doi:10.1002/cncr.24317 · Cited by 121
Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes
Shen, T. S., der Stadt, S. P.-V., Yeat, N. C., & Lin, J. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00215 · Cited by 115
O'Shannessy, D. J., Somers, E. B., Smale, R., & Fu, Y. (2013) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3182774562 · Cited by 113
Disis, M. L., Patel, M. R., Pant, S., Infante, J. R., Lockhart, A. C., Kelly, K. L., Beck, J. T., Gordon, M. S., Weiss, G. J., Ejadi, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5509 · Cited by 111
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients
Kalli, K. R., Block, M. S., Kasi, P. M., Erskine, C. L., Hobday, T. J., Dietz, A. B., Padley, D. J., Gustafson, M. P., Shreeder, B., Puglisi-Knutson, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2499 · Cited by 104
Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer
Kverneland, A. H., Pedersen, M., Westergaard, M. C. W., Nielsen, M., Borch, T. H., Olsen, L. R., Aasbjerg, G. N., Santegoets, S. J. A. M., van der Burg, S. H., Milne, K., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27604 · Cited by 101
Mourmouras, V., BIAGIOLI, M., Miracco, C., Luzi, P., Tosi, P., Cosci, E., Monciatti, I., Mannucci, S., & Rubegni, P. (2007) · Oncology Reports · doi:10.3892/or.18.5.1115 · Cited by 100
Oh, J., Barve, M. A., Matthews, C. M., Koon, E. C., Heffernan, T. P., Fine, B. A., Grosen, E. A., Bergman, M. K., Fleming, E. L., DeMars, L. R., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.09.018 · Cited by 96
Self-citationMonk, B. J., Brady, M. F., Aghajanian, C. A., Lankes, H. A., Rizack, T., Leach, J. W., Fowler, J. M., Higgins, R. V., Hanjani, P., Morgan, M. A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx049 · Cited by 94
Arias‐Pulido, H., Cimino‐Mathews, A., Chaher, N., Qualls, C., Joste, N. E., Colpaert, C., Marotti, J. D., Foisey, M. G., Prossnitz, E. R., Emens, L. A., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4834-7 · Cited by 92
Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer
Hylander, B. H., Repasky, E. A., Shrikant, P. A., Intengan, M., Beck, A. F., Driscoll, D., Singhal, P., Lele, S., & Odunsi, K. O. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.09.052 · Cited by 89
The Inhibitory Effect of Ellagic Acid on Cell Growth of Ovarian Carcinoma Cells
Chung, Y., Lu, L.-C., Tsai, M.-H., Chen, Y.-J., Chen, Y., Yao, S.-P., & Hsu, C. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/306705 · Cited by 87
Pellegrino, B., Musolino, A., Llop‐Guevara, A., Serra, V., Silva, P. D., Hlavata, Z., Sangiolo, D., Willard-Gallo, K. E., & Solinas, C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.10.010 · Cited by 81
BRCA mutation in high grade epithelial ovarian cancers
Manchana, T., Phoolcharoen, N., & Tantbírójn, P. (2019) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2019.07.007 · Cited by 78
Current Ovarian Cancer Maintenance Strategies and Promising New Developments
Gogineni, V., Morand, S. M., Staats, H., Royfman, R., Devanaboyina, M., Einloth, K. R., Dever, D., Stanbery, L., Aaron, P. A., Manning, L., et al. (2020) · Journal of Cancer · doi:10.7150/jca.49406 · Cited by 78
Self-citationZhang, W., Xu, L., Cui, P., Piao, C., Xiao, M., Liu, X., Wang, Y., Wu, X., Liu, J., & Yang, L. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2257-2 · Cited by 77
Role of DNA repair defects in predicting immunotherapy response
Zhang, J., Shih, D. J. H., & Lin, S. (2020) · Biomarker Research · doi:10.1186/s40364-020-00202-7 · Cited by 77
Plesca, I., Tunger, A., Müller, L., Wehner, R., Lai, X., Grimm, M., Rutella, S., Bachmann, M. P., & Schmitz, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00364 · Cited by 75
Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer
Roane, B. M., Arend, R. C., & Birrer, M. J. (2019) · Cancers · doi:10.3390/cancers11050668 · Cited by 74
Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma
Andersen, R. S., Donia, M., Westergaard, M. C. W., Pedersen, M., Hansen, M., & Svane, I. M. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1075106 · Cited by 68
Tumour-reactive T cell subsets in the microenvironment of ovarian cancer
Westergaard, M. C. W., Andersen, R. S., Chong, C., Kjeldsen, J. W., Pedersen, M., Friese, C., Hasselager, T., Lajer, H., Coukos, G., Bassani‐Sternberg, M., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0384-y · Cited by 68
Sarivalasis, A., Boudousquié, C., Balint, K., Stevenson, B. J., Gannon, P. O., Iancu, E. M., Rossier, L., Lluesma, S. M., Mathevet, P., Sempoux, C. L., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02133-w · Cited by 68
Autophagy as an emerging therapy target for ovarian carcinoma
Zhan, L., Zhang, Y., Wang, W., Song, E., Fan, Y., Li, J., & Wei, B. (2016) · Oncotarget · doi:10.18632/oncotarget.13080 · Cited by 64
Solinas, C., Marcoux, D., Garaud, S., Vitória, J. R., den Eynden, G. V., de Wind, A., Silva, P. D., Boisson, A., Craciun, L., Larsimont, D., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.027 · Cited by 64
Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
Zhu, J., Wen, H., Bi, R., Wu, Y., & Wu, X. (2017) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2017.28.e77 · Cited by 62
Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer
Benvenuto, M., Focaccetti, C., Izzi, V., Masuelli, L., Modesti, A., & Bei, R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.023 · Cited by 62
Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer
Walters, C. L., Arend, R. C., Armstrong, D. K., Naumann, R. W., & Alvarez, R. D. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.07.080 · Cited by 61
Sakellariou-Thompson, D., Forget, M., Creasy, C. A., Bernard, V., Zhao, L., Kim, Y. U., Hurd, M. W., Uraoka, N., Parra, E. R., Kang, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0831 · Cited by 60
Immunotherapy in ovarian cancer
Mantia-Smaldone, G. M., Corr, B. R., & Chu, C. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.20738 · Cited by 57
Association between tumor mutation burden and immune infiltration in ovarian cancer
Fan, S., Gao, X., Qin, Q., Li, H., Yuan, Z., & Zhao, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107126 · Cited by 57
Ledermann, J. A., Colombo, N., Oza, A. M., Fujiwara, K., Birrer, M. J., Randall, L. M., Poddubskaya, E. V., Scambia, G., Shparyk, Y. V., Lim, M.-C., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.06.025 · Cited by 56
The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies
Marinelli, O., Annibali, D., Aguzzi, C., Tuyaerts, S., Amant, F. C., Morelli, M. B., Santoni, G., Amantini, C., Maggi, F., & Nabissi, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01073 · Cited by 53
Moore, K. N., & Pignata, S. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2018-000071 · Cited by 51
Martinez‐Rodriguez, M., Thompson, A. K., & Monteagudo, C. C. (2014) · Histopathology · doi:10.1111/his.12437 · Cited by 43
Rocconi, R. P., Monk, B. J., Walter, A., Herzog, T. J., Galanis, E., Manning, L., Bognar, E., Wallraven, G., Stanbery, L., Aaron, P. A., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.03.009 · Cited by 37
Self-citationMorse, C. B., Elvin, J. A., Gay, L. M., & Liao, J. B. (2017) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2017.06.013 · Cited by 30
Hypermutated Tumors and Immune Checkpoint Inhibition
Ciombor, K. K., & Goldberg, R. M. (2018) · Drugs · doi:10.1007/s40265-018-0863-0 · Cited by 30
Sakellariou-Thompson, D., Forget, M., Hinchcliff, E., Celestino, J., Hwu, P., Jazaeri, A. A., Haymaker, C., & Bernatchez, C. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02402-z · Cited by 30
Nemunaitis, M. B. J. (2013) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000209 · Cited by 28
Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer
Liu, Y. L., Zhou, Q. C., Iasonos, A. E., Emengo, V. N., Friedman, C. F., Konner, J. A., O'Cearbhaill, R. E., Aghajanian, C. A., & Zamarin, D. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.08.006 · Cited by 21
Lee, J., Yi, J. Y., Kim, H. S., Lim, J. H.-J., Kim, S., Nam, B., Kim, H. S., Kim, J., Choi, C. H., Kim, B., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz085 · Cited by 18
BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target
Morand, S. M., Stanbery, L., Walter, A., Rocconi, R. P., & Nemunaitis, J. J. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa077 · Cited by 18
Self-citationCortellini, A., Bersanelli, M., Buti, S., Gambale, E., Atzori, F., Zoratto, F., Parisi, A., Brocco, D., Pireddu, A., Cannita, K., et al. (2018) · Immunotherapy · doi:10.2217/imt-2017-0167 · Cited by 17
Vigil: Personalized Immunotherapy Generating Systemic Cytotoxic T Cell Response
Herron, J. N., Smith, N., Stanbery, L., Aaron, P. A., Manning, L., Bognar, E., Wallraven, G., Horvath, S., & Nemunaitis, J. J. (2020) · Cancer Science & Research · doi:10.33425/2639-8478.1055 · Cited by 16
Self-citation
Cited by
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Metadata
- Authors
- Morand, S., Devanaboyina, M., Staats, H., Stanbery, L., & Nemunaitis, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-06-18
- Volume
- 22
- Issue
- 12
- Pages
- 6532
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3177399469
- Cited by
- 372
- References
- 147
- FWCI
- 41.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.